Barclays Initiates Coverage On PROCEPT BioRobotics with Overweight Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Neutral 51.1%

Neg 0% Neu 51.1% Pos 0%

Barclays analyst Christopher Pasquale initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight rating and announces Price Target of $30.